Eskitis installs Evotec's Opera

2 July 2006

Hamburg, Germany-based Evotec Technologies GmbH says that the Eskitis Institute of Australia's Griffith University, has installed the Opera system as its high-content screening platform.

With almost 40 installations to date, Evotec's Opera has become the most prominent system for combining high-throughput screening with high content analysis, the firm noted, adding that Opera combines the precision of confocal microscopy with the speed of primary screening instrumentation.

Commenting on the move, Guenter Bauer, Evotec's chief business officer, noted that "we see an increasing demand for fully-automated microscopy in academic research to cope with the high-throughput experimentation requirements of modern cell biology research."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight